View item

US Department of Defense – Amyotrophic Lateral Sclerosis Research Program – Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
Sponsor: US Department of Defense 		Closing Date: 21-Nov-2018
The FY19 Defense Appropriations Act provides USD $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis. The ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

The following mechanisms are planned for release:

Therapeutic Development Award
Eligibility
• Independent investigators at all academic levels

Key Mechanism Elements
• Pre-application is required; full application submission is by invitation only
• Supports post-discovery, preclinical advancement of therapeutics for ALS
• Preliminary data, including identify and purity of an identified bioactive compound(s), are required
• Clinical trials are not allowed
• Types of efforts that will be supported include:
- Confirmation of candidate therapeutics obtained from screening or by other means
- Validation of early pilot studies in multiple model systems and/or replicating preliminary data with more time points or additional doses
- Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices
- Investigational New Drug-enabling studies
• Optional Therapeutic Relevance Option:
- Applications proposing development of markers to improve the drug development process in parallel with the main therapeutic advancement effort and that meet the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding

Funding
• Maximum funding of USD $1,000,000 for direct costs (plus indirect costs)
• If applying for the Therapeutic Relevance Option, the maximum funding is USD $1,250,000 for direct costs (plus indirect costs)
• Maximum period of performance is 2 years

Therapeutic Idea Award
Eligibility
• Independent investigators at all academic levels

Key Mechanism Elements
• Pre-application is required; full application submission is by invitation only.
• Supports new ideas aimed at drug or treatment discovery that are still in the early stages of development
• Preliminary data are not required
• Types of efforts that will be supported include:
- Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality
- Development, modification, and use of high-throughput screens and novel model systems to define or assess lead compounds
• Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this award mechanism

Funding
• Maximum funding of USD $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 2 years

Key Dates
• Pre-application and application deadlines will be available when the Program Announcements are released, which is anticipated in November 2018.
• FY18 Pre-Applications for the Amyotrophic Lateral Sclerosis Research Program closed on 22 June 2018 and invited full applications closed on 11 October 2018. FY19 dates may be earlier than FY18 dates.

Interested applicants are strongly encouraged to make contact with the UQR&I international team (via internationalgrants@research.uq.edu.au) to discuss possible applications.
Website: http://cdmrp.army.mil/pubs/press/2019/19alsrppreann

Return